This trial is evaluating whether Nutrition/diet evaluation will improve 1 primary outcome and 31 secondary outcomes in patients with Hematologic Neoplasms. Measurement will happen over the course of 30 days.
This trial requires 70 total participants across 2 different treatment groups
This trial involves 2 different treatments. Nutrition/diet Evaluation is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
The signs and symptoms of non-Hodgkin lymphomas and Hodgkin disease can vary from person to person. The first symptoms may not be related to symptoms that are specific to the tumor itself. For example, the person may have a fever or feel tired with very little or no history of weight loss, enlargement of the spleen or lymph nodes, bone pain or night sweats. Diagnosis and treatment of non-Hodgkin lymphoma/Hodgkin disease can often be hindered by this presentation.
There is no cure for hematologic neoplasms. Treatment is very dependent on the specific patient; for example, the disease may have been present for a long time without an obvious presentation. Most treatments can be combined in multiple ways in treatment strategy.
Nearly 1 in 6 men in the United States could develop a hematologic malignancy. Men in the African-American subgroups had significantly higher than expected risks of all types of hematologic malignancies.
The data suggest that many hematologic neoplasms, including [chronic lymphocytic leukemia](https://www.withpower.com/clinical-trials/chronic-lymphocytic-leukemia), acute myelogenous leukemia, myelodysplastic syndromes, and acute promyelocytic leukemia, may be highly curable or even vanish without treatment after initial diagnosis, but the chances for remission were low. However, it is not yet possible to draw definite conclusions, since the studies were retrospective and all patients received no curative treatment.
Hematopoietic neoplasms are rare and are more common among the elderly. Chronic hepatitis B virus infection is the most common cause of hematopoietic neoplasm. The association of cancer with other diseases such as hepatitis B virus is not well understood. There are no hematologic neoplasms associated with immunodeficiency. The risk of malignancy is greater than that of the general population for disorders of immune function, particularly autoimmune diseases and transplantation.
Hematologic neoplasms, including all leukemia, lymphoma, and myeloma, are among the most common types of cancers and lead to serious consequences. They affect approximately one in four individuals and are the cause of death in one in four Americans with cancer. Hematologic neoplasms can be caused by genetic and environmental factors.
On average, persons diagnosed with a hematologic neoplasm in 1993 will have been 54.6 years old at the time of diagnosis. This is older than the ages of most people without a neoplasm, particularly with regard to the median ages of most other chronic conditions, but is not exceptionally so relative to most other cancers. For more specific purposes, particularly regarding specific hematologic neoplasms, a subset analysis based on exact diagnosis may be more meaningful than, e.g., the overall median age.
In adults with hematologic neoplasms, dietary assessment is not warranted unless there is suspicion of undernutrition. An initial meal intake (or on-demand) of one to two grams of carbohydrate/g body weight/day should be instituted in all patients regardless of stage of disease or body mass index.
Results from a recent paper indicate that nutrition/diet evaluation can help treat patients with low or low-normal nutritional values of protein intake (<0.8 g/kg) and a higher energy density (<2.0 kcal/g).
It is clear that other causes exist. The majority of primary hematologic neoplasms are not the result of human papillomavirus infection or genetic alterations in hematological stem cells. Infection with human T-lymphotropic virus types I and II has been postulated an important cause of malignant lymphoproliferative disorders. In addition, infection with Epstein-Barr virus, cytomegalovirus, and human foamyleukocytic leukoproliferative syndrome, have also been implicated.
Results from a recent paper discloses a significant contribution of MMs to hematologic neoplasms not elsewhere classified, indicating that hematological malignancies are part of a multi-hit syndrome in these hereditary cancers.
The [possible adverse effects of leukemia cells are (1) leukemia cells could penetrate the brain, eye and spine; (2) leukemia cells could be carried to and populate many parts of the body; and (3) leukemia cells could be metastasized and form malignant tumors that may invade various tissues and threaten health. All three of these events are serious threats to hematologic neoplasms.